OBJECTIVES: To determine if apolipoprotein E epsilon 4 influences the frequency of Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration and to determine if the frequency of Alzheimer-type pathologic features in synucleinopathies is similar to the frequency of such features in tauopathies and frontotemporal degeneration. METHODS: A total of 285 patients with pathologically proven neurodegenerative disorders, including diffuse and transitional Lewy body disease, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy, with a mean age of 75.1 +/- 9.3 years, were suitable for genetic and pathological analysis. Disorders were grouped as tauopathies (progressive supranuclear palsy and corticobasal degeneration), synucleinopathies (Lewy body disease and multiple system atrophy), and frontotemporal degeneration. Braak neurofibrillary tangle staging and quantitative scores of senile plaques were used to determine the degree of concomitant Alzheimer-type pathologic features in each case, and apolipoprotein E genotype was determined from DNA isolated from frozen brain tissue. The relationship of apolipoprotein E epsilon 4 to Alzheimer-type pathologic features was determined. RESULTS: Across all neurodegenerative disorders, apolipoprotein E epsilon 4 and older age independently predicted the co-occurrence of Alzheimer-type pathologic features (P<.001), whereas female sex had a lesser effect (P = .03). When divided into the 3 subgroups (tauopathies, synucleinopathies, and frontotemporal degeneration), apolipoprotein E epsilon 4 had a similar effect, whereas older age and female sex were less predictive. There was a significant difference between the frequency of Alzheimer-type pathologic features in synucleinopathies and the frequency of such features in tauopathies and frontotemporal degeneration (P<.001 for both). The frequency of apolipoprotein E epsilon 4 allele was not significantly different among the 3 groups. CONCLUSIONS: Apolipoprotein E epsilon 4, independent of older age and sex, contributes to the co-occurrence of Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration, but this does not explain why Alzheimer-type pathologic features are significantly more likely to coexist with synucleinopathies than with either tauopathies or frontotemporal degeneration.
OBJECTIVES: To determine if apolipoprotein E epsilon 4 influences the frequency of Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration and to determine if the frequency of Alzheimer-type pathologic features in synucleinopathies is similar to the frequency of such features in tauopathies and frontotemporal degeneration. METHODS: A total of 285 patients with pathologically proven neurodegenerative disorders, including diffuse and transitional Lewy body disease, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy, with a mean age of 75.1 +/- 9.3 years, were suitable for genetic and pathological analysis. Disorders were grouped as tauopathies (progressive supranuclear palsy and corticobasal degeneration), synucleinopathies (Lewy body disease and multiple system atrophy), and frontotemporal degeneration. Braak neurofibrillary tangle staging and quantitative scores of senile plaques were used to determine the degree of concomitant Alzheimer-type pathologic features in each case, and apolipoprotein E genotype was determined from DNA isolated from frozen brain tissue. The relationship of apolipoprotein E epsilon 4 to Alzheimer-type pathologic features was determined. RESULTS: Across all neurodegenerative disorders, apolipoprotein E epsilon 4 and older age independently predicted the co-occurrence of Alzheimer-type pathologic features (P<.001), whereas female sex had a lesser effect (P = .03). When divided into the 3 subgroups (tauopathies, synucleinopathies, and frontotemporal degeneration), apolipoprotein E epsilon 4 had a similar effect, whereas older age and female sex were less predictive. There was a significant difference between the frequency of Alzheimer-type pathologic features in synucleinopathies and the frequency of such features in tauopathies and frontotemporal degeneration (P<.001 for both). The frequency of apolipoprotein E epsilon 4 allele was not significantly different among the 3 groups. CONCLUSIONS:Apolipoprotein E epsilon 4, independent of older age and sex, contributes to the co-occurrence of Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration, but this does not explain why Alzheimer-type pathologic features are significantly more likely to coexist with synucleinopathies than with either tauopathies or frontotemporal degeneration.
Authors: Christian Wider; Owen A Ross; Kenya Nishioka; Michael G Heckman; Carles Vilariño-Güell; Barbara Jasinska-Myga; Nilufer Erketin-Taner; Rosa Rademakers; Neill R Graff-Radford; Deborah C Mash; Spiridon Papapetropoulos; Ranjan Duara; Hirotake Uchikado; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson Journal: J Neurol Neurosurg Psychiatry Date: 2012-01-30 Impact factor: 10.154
Authors: Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson Journal: Acta Neuropathol Date: 2014-03-23 Impact factor: 17.088
Authors: Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson Journal: J Neuropathol Exp Neurol Date: 2008-07 Impact factor: 3.685
Authors: Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Matthew L Senjem; Bradley F Boeve; David S Knopman; Glenn E Smith; Robert J Ivnik; Clifford R Jack; Ronald C Petersen Journal: Brain Date: 2011-01-20 Impact factor: 13.501
Authors: Georges Naasan; Gil D Rabinovici; Pia Ghosh; Jonathan D Elofson; Bruce L Miller; Giovanni Coppola; Anna Karydas; Jamie Fong; David Perry; Suzee E Lee; Jennifer S Yokoyama; William W Seeley; Joel H Kramer; Michael W Weiner; Norbert Schuff; William J Jagust; Lea T Grinberg; Mochtar Pribadi; Zhongan Yang; Renee Sears; Eric Klein; Kevin Wojta; Howard J Rosen Journal: Neurocase Date: 2015-06-04 Impact factor: 0.881
Authors: Janna Hackett Neltner; Erin Lynn Abner; Frederick A Schmitt; Stephanie Kay Denison; Sonya Anderson; Ela Patel; Peter T Nelson Journal: J Neuropathol Exp Neurol Date: 2012-12 Impact factor: 3.685
Authors: Shinsuke Fujioka; Christina Sundal; Audrey J Strongosky; Monica Case Castanedes; Rosa Rademakers; Owen A Ross; Carles Vilariño-Güell; Matthew J Farrer; Zbigniew K Wszolek; Dennis W Dickson Journal: Acta Neuropathol Date: 2012-11-04 Impact factor: 17.088
Authors: Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell Journal: Ann Neurol Date: 2020-09-12 Impact factor: 10.422
Authors: Jennifer Molano; Bradley Boeve; Tanis Ferman; Glenn Smith; Joseph Parisi; Dennis Dickson; David Knopman; Neill Graff-Radford; Yonas Geda; John Lucas; Kejal Kantarci; Maria Shiung; Clifford Jack; Michael Silber; V Shane Pankratz; Ronald Petersen Journal: Brain Date: 2009-11-04 Impact factor: 13.501